Methods of treating endometriosis and other noncancer gynecological disorders with hemp extract
A method for treating a noncancerous gynecological disorder comprising: administering to a patient and effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.
1. A composition for treatment of a noncancerous gynecological disorder (NCGD) selected from the group consisting of: endometriosis, an ovarian endometrioma, a deep endometriosis, dysmenorrhea, and fibroids; wherein the composition comprises between 1% and 99% by weight of a cannabis extract (CE) and wherein the CE of the composition comprises:
a. an extract selected from the group consisting of: a full spectrum hemp extract (FSHE), a broad spectrum hemp extract (BSHE), a cannabidiol (CBD) isolate, and combinations thereof;
b. a carrier at between 1% and 99% by weight of the composition;
c. one or more excipients at between 1% and 50% by weight of the composition; and
d. the CE formulated for administration oromucosally and intravaginally as two separate doses.
2. The composition of claim 1 wherein the composition is acidic with a pH between 3.5 and 6.
3. The composition of claim 1 wherein the CE comprises between 10 mg and 4,250 mg of cannabidiol (CBD).
4. The composition of claim 1 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% by weight of the composition.
5. The composition of claim 1 wherein the composition comprises an oil or a fat as a carrier.
6. The composition of claim 1 wherein the composition further comprises at least one additional cannabinoid at between 0.1% and 10% weight percentage of the composition wherein the at least one additional cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.
7. A composition for intravaginal application for treatment of a noncancerous gynecological disorder (NCGD) selected from the group consisting of:
endometriosis, an ovarian endometrioma, a deep endometriosis, dysmenorrhea, and fibroids; wherein the composition comprises between 1% and 99% by weight of a cannabis extract (CE) and wherein the CE of the composition comprises:
a. an extract selected from the group consisting of: a full spectrum hemp extract (FSHE), a broad spectrum hemp extract (BSHE), a cannabidiol (CBD) isolate, and combinations thereof;
b. between 0.1% and 10% of a cannabidiolic acid (CBDA) isolate;
c. a carrier at between 1% and 99% by weight of the composition; and
d. one or more excipients at between 1% and 50% by weight of the composition.
8. The composition of claim 7 wherein the composition is acidic with a pH between 3.5 and 6.
9. The composition of claim 7 wherein the CE comprises between 10 mg and 4,250 mg of cannabidiol (CBD).
10. The composition of claim 7 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% by weight of the composition.
11. The composition of claim 7 wherein the composition comprises an oil or a fat as a carrier.
12. The composition of claim 7 wherein the composition further comprises at least one additional cannabinoid at between 0.1% and 10% weight percentage of the composition wherein the at least one additional cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.